Sanofi Ousts CEO, Acquires Dynavax for $2.2B
What happened
Pharmaceutical giant Sanofi has ousted CEO Paul Hudson amid challenges in vaccine development and slow growth, naming the outgoing CEO of Merck as his surprise replacement. In a move to bolster its pipeline, Sanofi also completed its $2.2 billion acquisition of Dynavax, gaining access to vaccine and immunotherapy assets.
Why it matters
- Paul Hudson's departure follows a series of research and development setbacks, including failures in late-stage trials for potential blockbuster drugs. This increased pressure on Sanofi to strengthen its pipeline as its top-selling anti-inflammatory drug, Dupixent, faces loss of market exclusivity in the next decade. - The incoming CEO, Belén Garijo, has been the CEO of Merck KGaA since 2021, where she was the first woman to lead a major German blue-chip company. This marks a return for Garijo, who previously spent 15 years at Sanofi and notably oversaw the integration of Genzyme. - The Dynavax acquisition is centered on its adult hepatitis B vaccine, HEPLISAV-B, which is administered in two doses over one month. This offers faster protection compared to the traditional three-dose vaccines given over six months. - Through the acquisition, Sanofi also gains a promising shingles vaccine candidate, Z-1018, which is currently in Phase 1/2 clinical trials and could eventually compete with GSK's market-leading shot, Shingrix. - The purchase helps bolster Sanofi's adult vaccine unit, which has been heavily dependent on influenza shots and recently reported slipping sales. - The abrupt nature of Hudson's removal contrasts with recent, longer leadership transitions at other major European pharmaceutical companies like GSK and Novo Nordisk. - During Hudson's six-year tenure, Sanofi's stock price remained largely unchanged, significantly underperforming European rivals like AstraZeneca and GSK, whose investors saw returns of 133% and 65% respectively over the same period. - Following the announcement of the leadership change, Sanofi's shares fell by approximately 5%, indicating initial investor skepticism.
Key numbers
- In a move to bolster its pipeline, Sanofi also completed its $2.2 billion acquisition of Dynavax, gaining access to vaccine and immunotherapy assets.
- The incoming CEO, Belén Garijo, has been the CEO of Merck KGaA since 2021, where she was the first woman to lead a major German blue-chip company.
- This marks a return for Garijo, who previously spent 15 years at Sanofi and notably oversaw the integration of Genzyme.
- Through the acquisition, Sanofi also gains a promising shingles vaccine candidate, Z-1018, which is currently in Phase 1/2 clinical trials and could eventually compete with GSK's market-leading shot, Shingrix.
What happens next
- This increased pressure on Sanofi to strengthen its pipeline as its top-selling anti-inflammatory drug, Dupixent, faces loss of market exclusivity in the next decade.
- Through the acquisition, Sanofi also gains a promising shingles vaccine candidate, Z-1018, which is currently in Phase 1/2 clinical trials and could eventually compete with GSK's market-leading shot, Shingrix.
Quick answers
What happened in Sanofi Ousts CEO, Acquires Dynavax for $2.2B?
Pharmaceutical giant Sanofi has ousted CEO Paul Hudson amid challenges in vaccine development and slow growth, naming the outgoing CEO of Merck as his surprise replacement. In a move to bolster its pipeline, Sanofi also completed its $2.2 billion acquisition of Dynavax, gaining access to vaccine and immunotherapy assets.
Why does Sanofi Ousts CEO, Acquires Dynavax for $2.2B matter?
Paul Hudson's departure follows a series of research and development setbacks, including failures in late-stage trials for potential blockbuster drugs. This increased pressure on Sanofi to strengthen its pipeline as its top-selling anti-inflammatory drug, Dupixent, faces loss of market exclusivity in the next decade. The incoming CEO, Belén Garijo, has been the CEO of Merck KGaA since 2021, where she was the first woman to lead a major German blue-chip company. This marks a return for Garijo, who previously spent 15 years at Sanofi and notably oversaw the integration of Genzyme. The Dynavax acquisition is centered on its adult hepatitis B vaccine, HEPLISAV-B, which is administered in two doses over one month. This offers faster protection compared to the traditional three-dose vaccines given over six months. Through the acquisition, Sanofi also gains a promising shingles vaccine candidate, Z-1018, which is currently in Phase 1/2 clinical trials and could eventually compete with GSK's market-leading shot, Shingrix. The purchase helps bolster Sanofi's adult vaccine unit, which has been heavily dependent on influenza shots and recently reported slipping sales. The abrupt nature of Hudson's removal contrasts with recent, longer leadership transitions at other major European pharmaceutical companies like GSK and Novo Nordisk. During Hudson's six-year tenure, Sanofi's stock price remained largely unchanged, significantly underperforming European rivals like AstraZeneca and GSK, whose investors saw returns of 133% and 65% respectively over the same period. Following the announcement of the leadership change, Sanofi's shares fell by approximately 5%, indicating initial investor skepticism.
